Kymriah data maintains confidence in CAR-T therapies

11 December 2017
2019_biotech_test_vial_discovery_big

Six-month follow-up data on Kymriah (tisagenlecleucel) will bring relief at Swiss pharma giant Novartis (NOVN: VX) and at other drugmakers developing CAR-T therapies.

In August, Kymriah became the first CAR-T-cell-directed therapy to be approved by the US Food and Drug Administration (FDA). Its speedy approval came on the back of only mid-stage data and the FDA approved a Risk Evaluation and Mitigation Strategy (REMS) for the treatment, as part of which Novartis has been establishing a network of certified treatment centers throughout the USA.

"We have been able to significantly increase their chance of achieving and maintaining a sustained response without stem cell transplant"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology